Safiglipron
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects
Shandong Suncadia Medicine Co · Phase 1/2 · Completed · Enrollment 74
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Treatment group A | n/r | n/r | n/r | n/r |
| Treatment group B | n/r | n/r | n/r | n/r |
| Treatment group C | n/r | n/r | n/r | n/r |
| Treatment group D | n/r | n/r | n/r | n/r |
| Treatment group E | n/r | n/r | n/r | n/r |
| Treatment group F | n/r | n/r | n/r | n/r |
| Treatment group G | n/r | n/r | n/r | n/r |
| Treatment group H | n/r | n/r | n/r | n/r |
| Treatment group I | n/r | n/r | n/r | n/r |
| Treatment group J | n/r | n/r | n/r | n/r |
| Treatment group K | n/r | n/r | n/r | n/r |
| Treatment group L | n/r | n/r | n/r | n/r |
Not shown
- Treatment group A: endpoint not reported
- Treatment group B: endpoint not reported
- Treatment group C: endpoint not reported
- Treatment group D: endpoint not reported
- Treatment group E: endpoint not reported
- Treatment group F: endpoint not reported
- Treatment group G: endpoint not reported
- Treatment group H: endpoint not reported
- Treatment group I: endpoint not reported
- Treatment group J: endpoint not reported
- Treatment group K: endpoint not reported
- Treatment group L: endpoint not reported